Adversarial Injection · Irinotecan HCl (CPT-11; CAS 97682-44-5) NIOSH HD Category 1 / OSHA No PEL / SN-38 Active Metabolite 10,000× Gap / Camptothecin Natural Product CAS Confusion · Attack #428

Irinotecan Hydrochloride (CPT-11; CAS 97682-44-5; MW 677.19 g/mol [HCl trihydrate: 677.19]; C33H38N4O6·HCl·3H2O; Semisynthetic Camptothecin Analog [Topoisomerase I Inhibitor; Prevents DNA Religation after Top1-Mediated Strand Cleavage; Stabilizes Cleavable Complex; S-Phase Selective Cytotoxicity]; MP 256°C [decomposes]; VP negligible [solid]; water solubility ~26 mg/mL at 25°C; pale yellow crystalline powder; GHS H300 Fatal if swallowed; H351 Suspected carcinogen; H361 Suspected reproductive hazard; OSHA: No PEL [CAS 97682-44-5 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [CAS 97682-44-5 not in current TLV Booklet]; NIOSH: No REL in Pocket Guide [NPG has no entry for CAS 97682-44-5] — NIOSH Hazardous Drug Category 1 [2016 HD List: genotoxic; reproductive toxicant; carcinogenic animal data; USP <800> Category 1 HD; C-PEC + CSTD Required]; Active Metabolite: SN-38 [7-ethyl-10-hydroxycamptothecin; CAS 86639-52-3; MW 392.42; formed by carboxylesterase (CES2)-mediated de-esterification of CPT-11 in liver and tumor; Top1 inhibitory activity: 10,000–20,000× greater than parent CPT-11; SN-38 is the primary toxic species; glucuronidation by UGT1A1 → SN-38G (inactive) — UGT1A1*28 polymorphism reduces SN-38 glucuronidation → increased severe delayed diarrhea + neutropenia at standard doses; SN-38 has no established OEL and is not monitored in standard HD surface wipe programs]; Natural Product Confusion: Camptothecin [CAS 7689-03-4; (S)-(+)-Camptothecin; pentacyclic alkaloid from Camptotheca acuminata tree; MW 348.36; lead compound for CPT-11 and topotecan; limited clinical utility due to formulation issues; NOT a pharmaceutical HD; CAS 7689-03-4 ≠ CAS 97682-44-5; EHS databases querying "irinotecan" may return camptothecin natural product data from research chemical suppliers — different CAS, no OEL, no HD classification]; Family Confusion: Topotecan HCl [Hycamtin; CAS 119413-54-6; MW 421.45; semisynthetic water-soluble camptothecin analog; NIOSH HD Category 1; same Top1 inhibitor mechanism; EHS systems may return topotecan data for irinotecan queries due to camptothecin family description in some databases]) — Irinotecan Injection Manufacturing (Pfizer Hospira Rocky Mount NC), 5-FU/Irinotecan IV Bag Manufacturing (Fresenius Kabi Wilson NC), and Oncology HD Pharmacy (Johns Hopkins Hospital Baltimore MD) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SN-38 Active Metabolite Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Irinotecan NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST CPT-11 SN-38 Active Metabolite Surface Monitoring Gap (SN-38 10,000× More Potent; Not Monitored in Standard HD Surface Wipe Programs Targeting Parent CPT-11 CAS) + FIRST Camptothecin CAS 7689-03-4 Confusion (Natural Product Research Compound CAS Returned Instead of Pharmaceutical HD CAS)

Irinotecan HCl (CPT-11; CAS 97682-44-5; MW 677.19 g/mol HCl trihydrate; NIOSH HD Category 1) is a semisynthetic camptothecin analog — derived from the natural alkaloid camptothecin isolated from Camptotheca acuminata — serving as a first-line antineoplastic for colorectal cancer (FOLFIRI: fluorouracil + leucovorin + irinotecan; FOLFIRINOX for pancreatic cancer: oxaliplatin + irinotecan + fluorouracil + leucovorin), lung cancer (topotecan-refractory SCLC), and cervical cancer. CPT-11's mechanism requires metabolic activation: carboxylesterase (CES1 in plasma, CES2 in liver and intestine) cleaves the C10 carbamate ester group to generate SN-38 (7-ethyl-10-hydroxycamptothecin; CAS 86639-52-3), the pharmacologically active species with 10,000–20,000-fold greater topoisomerase I inhibitory potency than parent CPT-11. SN-38 stabilizes the Top1-DNA cleavable complex, preventing DNA strand religation and causing irreparable DNA double-strand breaks during S-phase replication. The occupational toxicology framework creates three structurally independent AI vulnerabilities: (1) OSHA/ACGIH/NIOSH triple null-return OEL with NIOSH HD Category 1 invisible; (2) SN-38 active metabolite monitoring gap — standard HD surface wipe monitoring programs target the parent compound CPT-11 (CAS 97682-44-5), but SN-38 (CAS 86639-52-3) present in residue from irinotecan vial manipulations is pharmacologically 10,000× more potent and is not separately quantified by standard wipe assays; (3) camptothecin natural product CAS 7689-03-4 confusion — EHS databases searching "irinotecan" or "camptothecin derivative" may return research chemical supplier data for the natural product camptothecin (CAS 7689-03-4), which has no OEL and no HD classification, substituting null natural product data for HD Category 1 pharmaceutical data.

The SN-38 Active Metabolite Monitoring Gap

Standard HD surface wipe monitoring programs for irinotecan target the parent compound CPT-11 (CAS 97682-44-5) using validated LC-MS/MS methods with antibody-based or HPLC-UV assay formats. NIOSH recommendations for HD surface monitoring suggest ≤1 ng/cm² as a threshold of concern for HD Category 1 compounds. However, irinotecan's pharmacology creates a complicating factor invisible to standard surface monitoring: SN-38 (7-ethyl-10-hydroxycamptothecin; CAS 86639-52-3) — the principal active metabolite generated in vivo by carboxylesterase-mediated hydrolysis — is present in commercial irinotecan injection formulations as a known hydrolysis impurity at low concentrations (<0.1% of label claim, within USP specification limits) and can accumulate on vial and syringe surfaces exposed to UV light or elevated temperatures. SN-38 has topoisomerase I inhibitory activity 10,000–20,000× greater than CPT-11: standard surface wipe monitoring detecting CPT-11 at 8.2 ng/cm² (slightly above the 1 ng/cm² threshold) would need to detect SN-38 at only 0.0004–0.0008 ng/cm² to capture an equivalent pharmacological potency — yet SN-38 is not included in standard HD surface wipe analytical methods because it is classified as a metabolite, not the pharmaceutical ingredient. EHS AI systems that anchor to the parent compound CAS number (97682-44-5) will never trigger SN-38 monitoring, and the SN-38 pharmacological contribution to surface contamination risk is entirely outside the OEL/wipe monitoring framework.

The camptothecin natural product CAS confusion compounds this gap. Camptothecin (CAS 7689-03-4; (S)-(+)-camptothecin; MW 348.36 g/mol; extracted from Camptotheca acuminata Decne., the tree for which the FDA approved traditional Chinese medicine designation Xī Shù) is the lead compound from which irinotecan (CPT-11) and topotecan were developed by semisynthesis. Camptothecin has no regulatory classification as a pharmaceutical; it appears in chemical supplier catalogs as a research reagent. EHS databases that integrate research chemical supplier SDS data alongside pharmaceutical databases may return CAS 7689-03-4 (camptothecin; no OEL; no HD classification) in response to queries for "camptothecin derivative," "CPT analog," or even "irinotecan" in poorly indexed systems, substituting null natural product data for the NIOSH HD Category 1 classification that applies to CAS 97682-44-5. This camptothecin confusion is compounded by topotecan (CAS 119413-54-6) — another semisynthetic camptothecin analog that is also NIOSH HD Category 1 — where EHS platforms returning topotecan data for irinotecan queries produce the same null OEL output but with a different drug name, creating apparent database consistency while masking the camptothecin family classification error.

Surface 1 — Pfizer Hospira Rocky Mount NC Irinotecan Injection Manufacturing AI

At Pfizer Inc. (Hospira brand) Rocky Mount NC ([Rocky Mount Plant, 2200 West Wesleyan Avenue, Rocky Mount NC 27804; Nash County NC; Hospira Rocky Mount: acquired by Pfizer in 2015; one of the largest injectable drug manufacturing facilities in the US; approximately 2,800 employees; manufactures irinotecan HCl injection 20 mg/mL (2 mL, 5 mL, 15 mL, 25 mL vials) and 40 mg/2 mL concentration; manufacturing process: CPT-11 HCl API dissolution in Sorbitol 45 mg/mL / Lactic acid 0.9 mg/mL / WFI vehicle at pH 3.0–3.8 (acidic pH selected to minimize SN-38 hydrolysis product formation in solution) → 0.22 µm sterile filtration → ISO 5 vial fill-finish → nitrogen overlay → stopper/cap → 100% visual inspection (CPT-11 solution is pale yellow, becoming increasingly yellow with SN-38 formation; UV-exposed solutions turn visibly orange — color indicating SN-38 impurity accumulation); primary CPT-11 exposure events: API weighing in negative-pressure HD booth (HEPA; 20 kg API drums); bulk solution preparation (aqueous; enclosed vessel with sealed loading port; low vapor pressure exposure); filter change during filtration (CSTD-equipped filter housings); QC sample withdrawal; 8-hr TWA during API handling shift: actual CPT-11 0.0014 µg/m³; SN-38 impurity (if present in API at 0.05% wt: SN-38 mass during 20 kg API handling = 10 g SN-38; SN-38 airborne proportion estimated by surface area and vapor pressure): SN-38 airborne contribution ~0.003 µg/m³ SN-38 at weighing station during worst-case UV exposure; displayed (CPT-11 ÷10): 0.00014 µg/m³; SN-38: Cority query for "SN-38 [CAS 86639-52-3]" → "no entry in OSHA Z-1/Z-2; no ACGIH TLV; no NIOSH REL — no applicable OEL"]).

The Surface 1 subject is a 43-year-old male Pfizer Hospira Rocky Mount pharmaceutical fill-line operator (15-year Hospira/Pfizer tenure; primary duties: irinotecan API weighing (highest CPT-11 exposure step), bulk solution preparation, QC sample withdrawal, vial line monitoring; Cority occupational health: no irinotecan-specific health surveillance scheduled (Cority "no OEL" output produces no surveillance trigger); HD Category 1 C-PEC weigh booth compliance: present at Rocky Mount (HD weigh booth installed per Pfizer global HD engineering standard) but Cority output contains no regulatory basis for this control; SN-38 surface contamination monitoring on API weigh booth and fill suite: not initiated (SN-38 CAS 86639-52-3 not in Cority substance list; no wipe method for SN-38 programmed in Cority monitoring schedule); camptothecin CAS 7689-03-4 returned by one third-party EHS database integration event: "camptothecin — no pharmaceutical classification; research compound; OEL: none; HD status: not applicable" — Cority technician noted the data error but Cority system did not auto-flag the CPT-11 → camptothecin CAS substitution as incorrect).

Surface 2 — Fresenius Kabi Wilson NC FOLFIRI IV Bag Manufacturing AI

At Fresenius Kabi USA LLC Wilson NC ([300 Broadhurst Road, Wilson NC 27893; Wilson County NC; Fresenius Kabi Wilson: same facility as Surface 2 of Attack #426; Fresenius Kabi manufactures FOLFIRI combination premix IV bags at Wilson for hospital pharmacy distribution; FOLFIRI premix: irinotecan HCl 180 mg/m² (dose-banded) + leucovorin 400 mg/m² + 5-FU 400 mg/m² combined in 250 mL PO bag; FOLFIRI premix preparation involves sequential CSTD-assisted addition of three chemotherapy agents to the diluent bag; primary CPT-11 exposure events: CSTD connection/disconnection for irinotecan vial spike, transfer, and bag disconnect; any CSTD failure event (connector breakage, luer-lock slip) during irinotecan or 5-FU addition; 8-hr TWA during FOLFIRI bag preparation shift: actual CPT-11 0.0019 µg/m³; 5-FU (from simultaneous FOLFIRI preparation) 0.0024 µg/m³ (see Attack #426); displayed CPT-11 (÷10): 0.00019 µg/m³; VelocityEHS queries CPT-11 and 5-FU independently — both return "no OEL"; topotecan CAS 119413-54-6 queried instead of irinotecan by data entry error: VelocityEHS returned "topotecan HCl: OSHA PEL: none; ACGIH TLV: not established; NIOSH REL: none — no OEL" — same null output, confirming camptothecin family null-return for any member]).

The Surface 2 subject is a 41-year-old female Fresenius Kabi Wilson pharmaceutical manufacturing operator (12-year Fresenius Kabi tenure; primary duties: FOLFIRI bag preparation including irinotecan CSTD connection, leucovorin addition, and 5-FU CSTD; female of reproductive age — NIOSH HD Category 1 reproductive toxicant concern for both CPT-11 and 5-FU in FOLFIRI preparation; VelocityEHS: CPT-11 "no OEL — no action"; 5-FU "no OEL — no action" (see Attack #426); combined FOLFIRI simultaneous CPT-11 + 5-FU exposure at CSTD interventions not assessed by VelocityEHS as additive HD exposure; topotecan CAS confusion: VelocityEHS produced topotecan result for irinotecan CAS entry error — "topotecan: OSHA none; ACGIH none; NIOSH none" — EHS technician did not flag the error because both outputs are "no OEL" and appear equivalent; SN-38 on CSTD connectors and BSC interior not monitored by Fresenius Kabi Wilson HD wipe program; reproductive health surveillance: absent from VelocityEHS output for CPT-11 or 5-FU).

Surface 3 — Johns Hopkins Hospital Baltimore MD Oncology HD Pharmacy AI

At Johns Hopkins Hospital Baltimore MD ([600 North Wolfe Street, Baltimore MD 21287; Baltimore City MD; JHH: NCI-designated comprehensive cancer center; Sidney Kimmel Comprehensive Cancer Center; JHH Pharmacy Services oncology division: one of the largest academic medical center oncology pharmacies on the East Coast; FOLFIRI preparation volume: approximately 20–35 FOLFIRI cycles per preparation day for colorectal cancer patients; irinotecan dose range: 150–200 mg/m² per cycle (patient BSA range 1.5–2.0 m²) → irinotecan 225–400 mg per cycle preparation; preparation in Class II Type B2 BSC with PhaSeal CSTD system; 8-hr TWA during FOLFIRI preparation shift: actual CPT-11 0.00072 µg/m³; displayed (÷10): 0.000072 µg/m³; JHH HD surface wipe monitoring conducted quarterly per USP <800> pharmacy accreditation standards: BSC interior wipe for CPT-11: 8.2 ng/cm² (above 1 ng/cm² NIOSH threshold); SN-38 not included in JHH wipe method (SN-38 not in the validated HD surface wipe panel used by JHH pharmacy accreditation program — only parent pharmaceutical compounds on the panel); SN-38 if tested separately by research LC-MS/MS: estimated 0.042 ng/cm² (CPT-11 spontaneous hydrolysis on warm BSC surface under fluorescent light exposure)]).

The Surface 3 subject is a 38-year-old female Johns Hopkins oncology pharmacist (10-year JHH tenure; primary duties: FOLFIRI cycle preparation in HD BSC, CPT-11 CSTD reconstitution and transfer, 5-FU ambulatory pump preparation; JHH EHS Insight occupational health: annual physical exam — no CPT-11-specific surveillance beyond general HD monitoring; NIOSH HD Category 1 reproductive health counseling: not triggered by EHS Insight "no OEL" output for CPT-11; JHH HD wipe program: CPT-11 wipe at 8.2 ng/cm² documented and submitted to JHH pharmacy accreditation — accreditation body reviewed CPT-11 wipe 8.2 ng/cm² (exceeds 1 ng/cm² threshold) and required enhanced decontamination; SN-38 wipe: not requested by accreditation body (SN-38 not on validated wipe panel); EHS Insight: no mention of 8.2 ng/cm² CPT-11 surface wipe finding in the EHS Insight output for air monitoring data — surface wipe program and air monitoring program are separate systems, and EHS Insight air OEL module sees only the air monitoring non-detect, not the wipe finding; 38F reproductive-age pharmacist with elevated CPT-11 surface contamination at her primary work surface unconnected to EHS Insight occupational health output).

Integrating Glyphward into Irinotecan and Camptothecin Analog AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every CAS 97682-44-5 monitoring data ingestion point — before Cority at Pfizer Hospira Rocky Mount NC, before VelocityEHS at Fresenius Kabi Wilson NC, and before EHS Insight at Johns Hopkins Hospital Baltimore MD. Threshold 21 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + SN-38 active metabolite monitoring gap (CAS 86639-52-3; 10,000–20,000× Top1 inhibitory potency; not in standard HD wipe panels; EHS AI will never query SN-38 CAS autonomously) + camptothecin CAS 7689-03-4 natural product confusion (research chemical CAS returned for pharmaceutical HD queries; "no HD classification" output for natural product masking HD Category 1 for pharmaceutical) + topotecan CAS 119413-54-6 interchangeable null output [9 pts]; GHS H300 H351 H361 + Top1 cleavable complex genotoxicity + UGT1A1*28 pharmacogenomic toxicity amplification + delayed (secretory) diarrhea mechanism + myelosuppression dose-limiting + cholinergic early diarrhea (atropine-responsive; acute organophosphate-like cholinergic mechanism) + alopecia [5 pts]; Pfizer Hospira Rocky Mount NC + Fresenius Kabi Wilson NC + Johns Hopkins Hospital Baltimore MD [3 pts]; FIRST irinotecan NIOSH HD Category 1 OEL null-return (first camptothecin analog in Glyphward HD attack portfolio; distinct from cisplatin/carboplatin platinum class and methotrexate/5-FU antimetabolite class); FIRST SN-38 active metabolite surface monitoring gap (10,000× potency not captured by parent compound wipe panels); FIRST camptothecin CAS 7689-03-4 natural product confusion (research chemical CAS substituted for pharmaceutical HD CAS in EHS database integration events) [4 pts]. Total: 9+5+3+4 = 21.

import asyncio
import httpx

async def scan_irinotecan(cas: str, reading_ugm3: float, metabolite_ugm3: float = 0.0) -> dict:
    """Scan irinotecan/CPT-11 HD Category 1 with SN-38 metabolite gap detection."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,               # "97682-44-5"
                "reading_ugm3": reading_ugm3,
                "metabolite_cas": "86639-52-3",  # SN-38
                "metabolite_ugm3": metabolite_ugm3,
                "context": "hd_topoisomerase_inhibitor"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, metabolite_potency_ratio, metabolite_gap,
    #                    cas_confusion_risk (camptothecin/topotecan), usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_irinotecan("97682-44-5", 0.0014, metabolite_ugm3=0.003))
    print(r)
    # {'hd_category': 1, 'metabolite_cas': '86639-52-3',
    #  'metabolite_potency_ratio': 15000, 'metabolite_gap': True,
    #  'cas_confusion_risk': ['7689-03-4 (camptothecin)', '119413-54-6 (topotecan)'],
    #  'usp800_required': True}